326 related articles for article (PubMed ID: 31202577)
21. BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes.
Sasanuma H; Tsuda M; Morimoto S; Saha LK; Rahman MM; Kiyooka Y; Fujiike H; Cherniack AD; Itou J; Callen Moreu E; Toi M; Nakada S; Tanaka H; Tsutsui K; Yamada S; Nussenzweig A; Takeda S
Proc Natl Acad Sci U S A; 2018 Nov; 115(45):E10642-E10651. PubMed ID: 30352856
[TBL] [Abstract][Full Text] [Related]
22. Canonical non-homologous end-joining promotes genome mutagenesis and translocations induced by transcription-associated DNA topoisomerase 2 activity.
Olmedo-Pelayo J; Rubio-Contreras D; Gómez-Herreros F
Nucleic Acids Res; 2020 Sep; 48(16):9147-9160. PubMed ID: 32749454
[TBL] [Abstract][Full Text] [Related]
23. Cellular processing pathways contribute to the activation of etoposide-induced DNA damage responses.
Fan JR; Peng AL; Chen HC; Lo SC; Huang TH; Li TK
DNA Repair (Amst); 2008 Mar; 7(3):452-63. PubMed ID: 18206427
[TBL] [Abstract][Full Text] [Related]
24. On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs.
Wu CC; Li YC; Wang YR; Li TK; Chan NL
Nucleic Acids Res; 2013 Dec; 41(22):10630-40. PubMed ID: 24038465
[TBL] [Abstract][Full Text] [Related]
25. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.
Toyoda E; Kagaya S; Cowell IG; Kurosawa A; Kamoshita K; Nishikawa K; Iiizumi S; Koyama H; Austin CA; Adachi N
J Biol Chem; 2008 Aug; 283(35):23711-20. PubMed ID: 18596031
[TBL] [Abstract][Full Text] [Related]
26. Physiological concentrations of glucocorticoids induce pathological DNA double-strand breaks.
Akter S; Shimba A; Ikuta K; Mahmud MRA; Yamada S; Sasanuma H; Tsuda M; Sone M; Ago Y; Murai K; Tanaka H; Takeda S
Genes Cells; 2023 Jan; 28(1):53-67. PubMed ID: 36415926
[TBL] [Abstract][Full Text] [Related]
27. Untangling trapped topoisomerases with tyrosyl-DNA phosphodiesterases.
Zagnoli-Vieira G; Caldecott KW
DNA Repair (Amst); 2020 Oct; 94():102900. PubMed ID: 32653827
[TBL] [Abstract][Full Text] [Related]
28. Untangling the roles of TOP2A and TOP2B in transcription and cancer.
Uusküla-Reimand L; Wilson MD
Sci Adv; 2022 Nov; 8(44):eadd4920. PubMed ID: 36322662
[TBL] [Abstract][Full Text] [Related]
29. Molecular mechanisms of topoisomerase 2 DNA-protein crosslink resolution.
Riccio AA; Schellenberg MJ; Williams RS
Cell Mol Life Sci; 2020 Jan; 77(1):81-91. PubMed ID: 31728578
[TBL] [Abstract][Full Text] [Related]
30. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide.
Wu CC; Li TK; Farh L; Lin LY; Lin TS; Yu YJ; Yen TJ; Chiang CW; Chan NL
Science; 2011 Jul; 333(6041):459-62. PubMed ID: 21778401
[TBL] [Abstract][Full Text] [Related]
31. Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel.
Maede Y; Shimizu H; Fukushima T; Kogame T; Nakamura T; Miki T; Takeda S; Pommier Y; Murai J
Mol Cancer Ther; 2014 Jan; 13(1):214-20. PubMed ID: 24130054
[TBL] [Abstract][Full Text] [Related]
32. Small Molecule Inhibitors Confirm Ubiquitin-Dependent Removal of TOP2-DNA Covalent Complexes.
Swan RL; Poh LLK; Cowell IG; Austin CA
Mol Pharmacol; 2020 Sep; 98(3):222-233. PubMed ID: 32587095
[TBL] [Abstract][Full Text] [Related]
33. MRN, CtIP, and BRCA1 mediate repair of topoisomerase II-DNA adducts.
Aparicio T; Baer R; Gottesman M; Gautier J
J Cell Biol; 2016 Feb; 212(4):399-408. PubMed ID: 26880199
[TBL] [Abstract][Full Text] [Related]
34. Genome-Wide CRISPR Screens Reveal ZATT as a Synthetic Lethal Target of TOP2-Poison Etoposide That Can Act in a TDP2-Independent Pathway.
Park JM; Zhang H; Nie L; Wang C; Huang M; Feng X; Tang M; Chen Z; Xiong Y; Lee N; Li S; Yin L; Hart T; Chen J
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047518
[TBL] [Abstract][Full Text] [Related]
35. DNA double-strand breaks with 5' adducts are efficiently channeled to the DNA2-mediated resection pathway.
Tammaro M; Liao S; Beeharry N; Yan H
Nucleic Acids Res; 2016 Jan; 44(1):221-31. PubMed ID: 26420828
[TBL] [Abstract][Full Text] [Related]
36. Studies on Non-synonymous Polymorphisms Altering Human DNA Topoisomerase II-Alpha Interaction with Amsacrine and Mitoxantrone: An
Farsani FM; Ganjalikhany MR; Vallian S
Curr Cancer Drug Targets; 2017; 17(7):657-668. PubMed ID: 27834128
[TBL] [Abstract][Full Text] [Related]
37. DNA fragility at topologically associated domain boundaries is promoted by alternative DNA secondary structure and topoisomerase II activity.
Raimer Young HM; Hou PC; Bartosik AR; Atkin ND; Wang L; Wang Z; Ratan A; Zang C; Wang YH
Nucleic Acids Res; 2024 Apr; 52(7):3837-3855. PubMed ID: 38452213
[TBL] [Abstract][Full Text] [Related]
38. RAD54L2-mediated DNA damage avoidance pathway specifically preserves genome integrity in response to topoisomerase 2 poisons.
Zhang H; Xiong Y; Sun Y; Park JM; Su D; Feng X; Keast S; Tang M; Huang M; Wang C; Srivastava M; Yang C; Zhu D; Chen Z; Li S; Yin L; Pommier Y; Chen J
Sci Adv; 2023 Dec; 9(49):eadi6681. PubMed ID: 38055811
[TBL] [Abstract][Full Text] [Related]
39. The role of topoisomerase II beta on breakage and proximity of RUNX1 to partner alleles RUNX1T1 and EVI1.
Smith KA; Cowell IG; Zhang Y; Sondka Z; Austin CA
Genes Chromosomes Cancer; 2014 Feb; 53(2):117-28. PubMed ID: 24327541
[TBL] [Abstract][Full Text] [Related]
40. Increasing the distance between two monomers of topoisomerase IIβ under the action of antitumor agent 4β-sulfur-(benzimidazole) 4'-demethylepipodophyllotoxin.
Sun LY; Zhu LW; Tang YJ
Sci Rep; 2018 Oct; 8(1):14949. PubMed ID: 30297860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
